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Abstract
Background: Advanced cancer is a multifactorial disease that demands treatments targeting multiple cellular 
pathways. Chinese herbal cocktail which contains various phytochemicals may target multiple dys-regulated pathways 
in cancer cells and thus may provide an alternative/complementary way to treat cancers. Previously we reported that 
the Chinese herbal cocktail Tien-Hsien Liguid (THL) can specifically induce apoptosis in various cancer cells and have 
immuno-modulating activity. In this study, we further evaluated the anti-metastatic, anti-angiogenic and anti-tumor 
activities of THL with a series of in vitro and in vivo experiments.
Methods: The migration and invasion of cancer cells and endothelial cells was determined by Boyden chamber 
transwell assays. The effect of THL on pulmonary metastasis was done by injecting CT-26 colon cancer cells 
intravenously to syngenic mice. The in vitro and in vivo microvessel formation was determined by the tube formation 
assay and the Matrigel plug assay, respectively. The in vivo anti-tumor effect of THL was determined by a human MDA-
MB-231 breast cancer xenograft model. The expression of metalloproteinase (MMP)-2, MMP-9, and urokinase 
plasminogen activator (uPA) was measured by gelatin zymography. The expression of HIF-1α and the phosphorylation 
of ERK1/2 were determined by Western blot.
Results: THL inhibited the migration and invasion ability of various cancer cells in vitro, decreased the secretion of 
MMP-2, MMP-9, and uPA and the activity of ERK1/2 in cancer cells, and suppressed pulmonary metastasis of CT-26 
cancer cells in syngenic mice. Moreover, THL inhibited the migration, invasion, and tube formation of endothelial cells 
in vitro, decreased the secretion of MMP-2 and uPA in endothelial cells, and suppressed neovascularization in Matrigel 
plugs in mice. Besides its inhibitory effect on endothelial cells, THL inhibited hypoxia-induced HIF-1α and vascular 
endothelial growth factor-A expression in cancer cells. Finally, our results show that THL inhibited the growth of human 
MDA-MB-231 breast cancer xenografts in NOD-SCID mice. This suppression of tumor growth was associated with 
decreased microvessel formation and increased apoptosis caused by THL.
Conclusion: Our data demonstrate that THL had broad-spectra anti-cancer activities and merits further evaluation for 
its use in cancer therapy.
Background
Metastasis, or the spread of cancer from its primary site
to a distant organ, is the main cause of death in patients
with malignancy [1]. Metastasis of cancer cells involves
multiple processes and various cytophysiological changes
[2]. To metastasize, cancer cells first lose the ability to
adhere to neighboring tumor cells and gain migratory
and invasive capabilities. Cancer cells can then permeate
the basement membrane, invade surrounding tissues and
gain direct access to blood and lymphatic vessels via
which cancer cells can disseminate throughout the body.
During this process, degradation of the extracellular
matrix and components of the basement membrane by
proteases, such as matrix metalloproteinase (MMP)-2,
MMP-9, and urokinase plasminogen activator (uPA),
plays a critical role in tumor invasion and metastasis [3-
6]. Patients with metastatic cancers can no longer be
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cured by local therapy alone and usually die after painful
chemotherapy. Thus control of cancer metastasis is an
important issue in tumor treatment.
Angiogenesis, the process of new blood vessel forma-
tion, plays a crucial role in the growth and metastasis of
tumors [7]. Tumor growth and progression require angio-
genesis because in its absence tumor growth is restricted
to a few millimeters in diameter due to the physical con-
straint set by simple diffusion of nutrients and oxygen. In
addition, angiogenesis and vascularization allows meta-
static tumor cells escape into the circulation and lodge in
other organs [7,8]. As a tumor expands, local hypoxic
conditions induce a molecular response in tumor cells,
leading to the activation of a key transcription factor, the
hypoxia-inducible factor (HIF) [9]. This transcription fac-
tor induces the expression of pro-angiogenic growth fac-
tors, such as vascular endothelial growth factor (VEGF),
which in turn bind to and activate their respective recep-
tors on the surface of endothelial cells, leading to angio-
genesis [10,11]. Since angiogenesis plays a prominent role
in tumor growth and metastasis, inhibition of angiogene-
sis is considered to be an important strategy for cancer
therapy [12,13].
Advanced cancer is a multifactorial disease that
demands treatments targeting multiple cellular pathways.
The fact that chemotherapy using cytotoxic anti-cancer
drugs has significant side effects and offers little survival
benefit for patients with advanced malignancies has
prompted the use of alternative medicine in cancer treat-
ment. Chinese/Oriental herbal medicine, an ancient and
complete medicinal system based on empirical observa-
tions, has long been used for treatment of malignancies.
Whereas single herbs are seldom used alone for cancer
treatment, herbal cocktails containing extracts from sev-
eral herbs are often used. A number of herbal cocktails
have been reported to have anti-tumor activities [14-19]
and some of them have been used by cancer patients for
many years. However, herbal remedies are yet to be inte-
grated into main stream medicine mainly due to lack of
experimental and clinical studies on their safety, efficacy,
and pharmacological mechanisms [20]. Careful in vitro
and in vivo studies will be essential and necessary to eval-
uate their efficacy and safety before clinical trials can be
contemplated.
Herbal cocktail may target multiple cellular pathways to
correct the dys-regulated cellular functions accompany-
ing different stages of cancer development. It is believed
that a properly formulated herbal cocktail which takes
advantage of synergy and interactions among a myriad of
phytochemicals present in the different herbs may
achieve better therapeutic efficacy than single herbs. The
Chinese herbal cocktail, Tien-Hsien Liquid (THL, pre-
pared by China-Japan Feida Union Co., Ltd., Hong Kong),
is a herbal mixture that has been used as an anticancer
dietary supplement for more than 15 years and has been
used by many cancer patients with favorable results in
over 15 countries. Moreover, our previous studies indi-
cate that it has immuno-modulating activity [21,22] and
can specifically induce apoptosis in a wide variety of can-
cer cells [23]. THL is an aqueous preparation of herbal
mixture and consists mainly of extracts from 14 Chinese
medicinal herbs: Cordyceps sinensis (CS),  Oldenlandia
diffusa (OD), Indigo pulverata levis (IPL; also known as
Indigo Naturalis),  Polyporus umbellatus (PU),  Radix
astragali (RA), Panax ginseng (PG), Solanum nigrum L.
(SNL), Pogostemon cablin (PC), Atractylodis macrocepha-
lae rhizoma (AMR), Trichosanthes radix (TR), Clematis
radix (CR), Margarite (M), Ligustrum lucidum Ait (LLA),
and Glycyrrhiza radix (GR) [21-23]. Among these con-
stituent herbs, the following herbs or their components
have been shown to have anti-tumor activity: CS [24-27],
OD [28,29], IPL [30,31], PU [32,33], RA [34-37], PG [38-
40], SNL [41], TR [42,43], CR [44], LLA [34], and GR
[45,46]. Moreover, whereas CS [27,47], PG [48,49], GR
[50,51] and OD [52] have been shown to inhibit tumor
metastasis, PG [39,48,49], GR [53] and SNL [54] have
been shown to have anti-angiogenic activity. These
results suggest that THL may have inhibitory effect on
tumor growth, metastasis and angiogenesis. In this study,
we evaluated the anti-metastatic, anti-angiogenic and
anti-tumor effects of THL with a series of in vitro and in
vivo pre-clinical experiments. Our data indicate that THL
had anti-metastatic, anti-angiogenic, and anti-tumor
activities. These results support the merit of this herbal
cocktail for therapy of various cancers.
Methods
Cell culture
The human lung carcinoma cell line, H1299, and the
mouse colon carcinoma cell line, CT-26, were routinely
grown in Dulbecco's modified Eagle medium (GIBCO
BRL Life Technologies, Grand Island, NY) supplemented
with 10% fetal bovine serum (FBS) in 5% CO2. The
human breast adenocarcinoma cell line, MDA-MB-231,
was cultured in DMEM/F-12 1:1 medium (GIBCO BRL
Life Technologies) supplemented with 10% FBS in 5%
CO2. The human prostate adenocarcinoma cell line, PC-
3, was cultured in RPMI-1640 medium (GIBCO BRL Life
Technologies) supplemented with 10% FBS in 5% CO2.
The human microvascular endothelial cell line-1
(HMEC-1) was cultured in MCDB131 medium (GIBCO
BRL Life Technologies) supplemented with 10% FBS, 10
ng/ml epidermal growth factor (Becton Dickinson, San
Jose, CA), and 1 mg/ml hydrocortisone (Sigma-Aldrich,
Inc., St. Louis, MO) in 5% CO2. Primary human umbilical
vein endothelial cells (HUVEC) were isolated from
umbilical cord as described [55] and maintained inChia et al. BMC Cancer 2010, 10:175
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medium 199 (GIBCO BRL Life Technologies) supple-
mented with 20% FBS, 30 μg/ml endothelial cell growth
supplement (Upstate Biotechnology, Lake Placid, NY), 15
μg/ml heparin (Leo Pharmaceutical Product, Ballerup,
Denmark), and 1 mM pyruvate in 5% CO2.
Handling of THL
For the in vitro experiments, the culture medium con-
taining THL was prepared as follows. THL (obtained
from China-Japan Feida Union Co., Ltd., Hong Kong) was
centrifuged to remove insoluble ingredients, and the
supernatant was added to the appropriate culture
medium to the final concentrations of 0.1, 0.25, 0.5, 0.75
or 1% (v/v). For the in vivo pulmonary metastasis experi-
ment, THL was used directly (without centrifugation
before use). For the breast cancer xenograft experiment,
THL was centrifuged to remove insoluble ingredients,
and the supernatant was diluted with phosphate-buffered
saline (PBS) at 1:1 (v/v) ratio.
Preparation of conditioned medium of MDA-MB-231 
cancer cells (231-CM)
2 × 106 MDA-MB-231 cells were incubated for 24 h in 5
ml of serum-free medium. The medium was then col-
lected, filtrated to remove cell debris, and stored at -20°C
until use. For mouse Matrigel plug assays, the condi-
tioned medium was concentrated 50 fold before use.
Wound healing migration assay
Cancer cells were seeded at a density of 1-5 × 105cells/
well in 12-well culture plates and allowed to form a con-
fluent monolayer. The layer of cells was then scraped with
a 20-200 μl micropipette tip to create a wound of ~1 mm
width. Cells were then washed twice with fresh medium,
and replaced with medium containing indicated concen-
tration of THL. After incubation at 37°C for 20 h, cells
were washed with PBS, fixed with 4% paraformaldehyde,
and stained with 0.5% Coomassie Brilliant Blue. Images of
the wounds were captures at 0 h and 20 h after scraping at
100-fold magnification and the average distance of the
wound was calculated by using Image Pro Plus software
(Media Cybernetics, Bethesda, MD). The ability of the
cells to close the wound, that is, their motility, was calcu-
lated in the following way: (average distance of the wound
at 0 h - average distance of the wound at 20 h/average dis-
tance of the wound at 0 h) × 100.
Migration and invasion assays
The in vitro cell migration and invasion assays were per-
f o r m ed  b y  u s i n g  a  m od i f i e d  Bo y d e n  c h a m be r  i n s e r t ed
with polyethylene terephthalate filter membrane contain-
ing 8-μm pores in 24-well plates (Millipore, Billerica,
MA). For cell invasion assays, the filter membranes were
coated with Matrigel (30 μg, Becton Dickinson, San Jose,
CA).
Cells (1 × 105) suspended in 200 μl of serum-free
medium were seeded onto the upper compartment of the
transwell chamber. The lower chamber was filled with
serum-free medium containing chemoattractants (10%
FBS for migration and invasion of cancer cells; 231-CM
for migration and invasion of endothelial cells) and vari-
ous concentrations of THL. After incubation for 6 h (for
migration assays) or 24 h (for invasion assays), the
medium in the upper chamber was removed and the fil-
ters were fixed with 70% ethanol for 10 min. The cells
remaining on the upper surface of the filter membrane
were then completely removed by wiping with a cotton
swab, and the cells on the opposite surface of the filter
membrane were stained with 0.5% Coomassie Brilliant
Blue for 10 min. The migrated/invaded cells were then
visualized and counted from six randomly selected fields
(× 200 magnification) under an inverted microscope.
Zymography
Production of MMPs and uPA by cancer or endothelial
cells were analyzed by gelatin and plasminogen-casein
zymography, respectively. In MMP gelatin zymography,
cells were cultured in serum-free medium with various
concentration of THL for 24 h (cancer cells) or 6 h
(endothelial cells), and conditioned media were collected,
filtrated, and concentrated (~50 fold). Equal amount of
conditioned medium samples were mixed with SDS sam-
ple buffer containing 2% SDS without β-mercaptoethanol
and applied, without boiling, to 7.5% SDS polyacrylamide
gels copolymerized with 2 mg/ml gelatin (Sigma-Aldrich,
Inc., St. Louis, MO). After electrophoresis, gels were
washed for 30 min at room temperature with gentle agita-
tion in renaturing buffer (2.5% Triton X-100 in H2O) to
remove SDS. The gels were then equilibrated in develop-
ing buffer (40 mM Tris-HCl, pH 7.4, 200 mM NaCl, 10
mM CaCl2) at room temperature with gentle agitation for
30 min. After removing the old developing buffer, the gels
were incubated in fresh developing buffer at 37°C over-
night. The gels were then stained with 0.5% Coomassie
Brilliant Blue and destained. The MMP activities were
visualized as clear bands against the blue background of
the stained gels. The uPA zymography was performed as
described in the MMP gelatin zymography, except that
the SDS polyacrylamide gels containing 1 mg/ml casein
(MP Biomedicals, Inc., Irvine, CA) and 1 U/ml plasmino-
gen (MP Biomedicals, Inc.) were used.
Pulmonary metastasis assay
All animal experiments in this study were performed fol-
lowing the Guidelines for Animal Experiments in
National Taiwan University and were approved by the
Institutional Animal Care and Use Committee in College
of Medicine, National Taiwan University (IACUC
Approval No: 20060184). Balb/c female mice (6-8 weeksChia et al. BMC Cancer 2010, 10:175
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old) were purchased from Laboratory Animal Center at
College of Medicine, National Taiwan University (Taipei,
Taiwan) and given food and water ad libitum. The mice
were oral fed with either THL or water (200 μl; twice a
day) throughout the experimental duration. On Day 8 of
treatment, the mice were injected intravenously (via tail
veins) with 2 × 105 mouse CT-26 colon cancer cells to
establish pulmonary metastasis. Mice were killed 15 days
after tumor cell injection and the metastatic nodules on
the surface of the lungs were counted. The lungs were
fixed with formalin. Thin sections were stained with
hematoxylin and eosin. Representative fields (at × 40 or ×
100 magnification) for each group were photographed.
Tube formation assay
Tube formation of HUVEC and HMEC-1 endothelial
cells on Matrigel was performed as described [56]. Matri-
gel (200 μl) was added to 24-well plates and allowed to
solidify for 30 min at 37°C. Endothelial cells (5 × 104 cells/
well) suspended in 500 μl of complete medium or 231-
CM containing various concentration of THL were
seeded on the solidified Matrigel. After incubation for 5
h, cells were fixed with 4% paraformaldehyde and stained
with 0.1% crystal violet in 20% methanol. Randomly cho-
sen fields were photographed at × 100 magnification and
the closed networks of vessel-like tubes were counted.
Mouse Matrigel plug assay
Female NOD-SCID mice (6-8 weeks old) were purchased
from Laboratory Animal Center at College of Medicine,
National Taiwan University and housed in pathogen-free
condition. The mice were subcutaneously injected with
500 μl of Matrigel containing concentrated 231-CM (10
μl), heparin (10 U) and either THL (5 μl) or water (5 μl).
F ou rt ee n da ys la t e r , m ic e  we r e ki lled and t he  M a t rig e l
plugs were removed. To quantitate the formation of func-
tional blood vessel, the amount of hemoglobin was mea-
sured using the Drakin's reagent kit (Sigma-Aldrich, St
Louis, MO).
Human MDA-MB-231 breast cancer xenograft model
Female NOD-SCID mice (6-8 weeks old) were purchased
from Laboratory Animal Center at College of Medicine,
National Taiwan University and housed in pathogen-free
condition throughout the experimental duration. Mice
were given free access to commercial rodent chow and
water. MDA-MB-231 cancer cells (3 × 106, suspended in
100 μl of PBS) were injected subcutaneously into both
flanks of the mouse. One week after tumor cell inocula-
tion, the mice were randomly divided into two groups.
The weight of the mice in these two groups was similar at
this time point. One group was intraperitoneally injected
with 100 μl of PBS-diluted THL [1:1 (v/v) dilution] once a
day until the end of the experiment (It should be noted
that the dosage of THL was optimized in our preliminary
experiments and that the THL dose used here showed no
toxic effect to the mice). The other group was adminis-
trated with PBS using similar protocol as described
above. The mouse body weight and tumor size were mea-
sured at different time points following tumor implanta-
tion, and the tumor volume was calculated according to
the following formula: 1/2 (Length × Width2). The
tumors were removed at Day 36 after tumor implanta-
tion, photographed, and weighed. The tumors were snap-
frozen in liquid nitrogen for immunohistochemical (IHC)
and TUNEL analyses.
IHC and TUNEL analyses
Cryostat sections of frozen tumors were fixed with 4%
paraformaldehyde, washed with PBS, and the endoge-
nous peroxidase activity was blocked with Dako Dual
endogenous enzyme block (Dako, Glostrup, Denmark).
After washing with PBS, the sections were blocked with
5% FBS in PBS. To detect CD31-positive stained microve-
ssels, the sections were probed with rat anti-CD31 anti-
body  (Becton Dickinson, San Jose, CA), and then
incubated with horseradish peroxidase-conjugated sec-
ondary antibody by using Rat on Mouse HRP-Polymer
Kit (Biocare Medical, Concord, CA). Following color
development by using Dako DAB reagent (Dako), the
nuclei were stained with hematoxyline. The sections were
then sealed with glycerol-gelatin (Sigma-Aldrich, Inc., St.
Louis, MO) for microscopic observation. Randomly cho-
sen fields were photographed at × 200 magnification and
the number of CD31-positive stained blood vessels was
counted. For TUNEL assay, the cryostat sections were
fixed in 4% paraformaldehyde, washed with PBS and per-
meated with permeabilization solution (0.1% T riton X -
100, 0.1% sodium citrate in PBS). The sections were then
labeled with TUNEL reaction mixture according to the
protocol provided by the manufacturer (Roche Applied
Science, Mannheim, Germany) to detect apoptotic cells.
Following TUNEL reaction, the sections were rinsed
three times with PBS, and incubated in Hoechest 33258
solution to label nuclear DNA. The sections were then
sealed with mounting medium (Sigma-Aldrich, Inc.) and
subjected to fluorescence microscopy. Randomly chosen
fields were photographed at × 200 magnification and the
number of TUNEL-positive cells was counted.
Statistical analyses
Data are present as the mean ± SD. The significance of
the difference between groups was evaluated with the
Student's t-test, p < 0.05 was considered significant.
Results
THL inhibits the migration ability of various cancer cells
Metastasis consists of sequential steps involving cancer
cell migration and invasion. To study whether THL had
an anti-metastatic effect, four highly invasive cancer cellChia et al. BMC Cancer 2010, 10:175
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lines, including PC-3 (human prostate cancer cells),
MDA-MB-231 (human breast cancer cells), H1299
(human lung cancer cells), and CT-26 (mouse colon can-
cer cells) [57-60], were used. We first tested the effect of
THL on the motility of cancer cells by the wound healing
assay. Confluent PC-3 cancer cells were scraped with a
sterilized tip as shown in Fig 1A, left panel. Cancer cells
were then allowed to migrate into the gap created by the
scraping either in the absence or presence of THL. After
20 h incubation, the gap remained unfilled by the
migrated cells in the THL-treated group was wider than
that in the untreated group (Fig 1A, right panel), indicat-
ing that THL can inhibit the motility of PC-3 cancer cells.
Similar wound healing assays were also performed with
MDA-MB-231, H1299, and CT-26 cancer cells in the
presence of various concentrations of THL. As shown in
Fig 1B, THL could inhibit the migration ability of all these
cancer cells in a dose-dependent manner. We also tested
the effect of THL on the migration of MDA-MB-231,
H1299, PC-3, and CT-26 cancer cells by the Boyden
chamber transwell assay. In all the cell lines tested, the
number of cells migrated to the lower chamber was
reduced by THL in a concentration-dependent manner
(Fig 1C). The inhibitory effect of THL on the migration of
these cancer cells is not due to the cytotoxic effect of
THL, because the viability of these cancer cells was barely
affected by THL in the concentration range tested (see
Additional file 1: Supplemental figure S1). Together, these
data further confirm that THL can inhibit the migration
ability of cancer cells.
THL inhibits the invasion ability of cancer cells
We next tested whether THL could inhibit the invasion
ability of cancer cells. The invasion property of MDA-
MB-231, H1299, PC-3, and CT-26 cancer cells was ana-
lyzed in the Matrigel-coated Boyden chamber in the pres-
ence of various concentrations of THL. In all the cell lines
tested, the number of cells invaded through the Matrigel-
coated filter was reduced by THL dose-dependently (Fig
1D), indicating that THL can inhibit the invasion ability
of these cancer cells.
MMP-2, MMP-9, and uPA are known to be involved in
the degradation of extracellular matrix and play a critical
role in tumor invasion and metastasis. We thus tested
whether THL could inhibit the secretion of MMP-2,
MMP-9, and uPA in cancer cells. Gelatin zymography
assays indicated that THL dose-dependently inhibited
the secretion of MMP-2 and MMP-9 in MDA-MB-231,
H1299, PC-3 and CT-26 cancer cells (Fig 2A). Real-time
RT-PCR analysis indicated that THL could inhibit the
transcription of the MMP-2 and MMP-9 genes in MDA-
MB-231 cells (see Additional file 2: Supplemental figure
S2). We also examined whether THL directly affected
MMP enzymatic activity. Conditioned medium of
untreated CT-26 cells was loaded into a single wide lane
on gelatin-containing gel, electrophoresed, and the gel
was divided into four strips. The gel strips were then
incubated in developing buffer containing various con-
centrations of THL. As shown in Fig 2B, THL could
inhibit MMP-2 activity directly in a dose-dependent
manner. To study whether THL could inhibit the secre-
t i o n  o f  u P A  i n  c a n c e r  c e l l s ,  c a s e i n  z y m o g r a p h y  a s s a y s
were performed. As shown in Fig. 2C, THL dose-depend-
ently inhibited the secretion of uPA in MDA-MB-231 and
H1299 cells.
The extracellular signal-regulated kinase (ERK) signal-
ing pathway is known to up-regulate the expression of
MMPs [61]. We thus tested the effect of THL on the ERK
signaling pathway. We found that THL could inhibit the
phosphorylation of ERK1/2 but not that of AKT (Fig 2D)
in CT-26 cancer cells, indicating that THL can inhibit the
ERK signaling pathway but not the phosphatidylinositol-
3-OH kinase (PI3K)/AKT signaling pathway.
THL inhibits the pulmonary metastasis of mouse CT-26 
colon cancer cells in mice
In light of the above findings, we next tested the ability of
THL to inhibit the experimental lung metastasis pro-
duced by an intravenous injection of CT-26 cancer cells
to the syngenic Balb/c mice. The mice were fed THL or
water throughout the experimental duration. Fifteen days
after tumor inoculation, the mice were sacrificed and the
tumor nodules on the surface of the lung were counted
and photographed (Fig 3A). The average number of
tumor nodules in water-fed group was 79 while that in
the THL-fed group was 48 (Fig 3B), indicating that THL
treatment significantly decreased tumor colonization in
the lung. Histological examination of the lung sections
showed that the lungs of the water-fed mice were filled
with metastasized CT-26 cells (Fig 3C). In contrast, the
lungs of the THL-fed mice contained much less metasta-
sized CT-26 cells and looked much more normal mor-
phologically (Fig 3C). Together, these results strongly
suggest that THL can inhibit cancer metastasis and could
be useful for prevention of cancer metastasis and recur-
rence in cancer patients.
THL inhibits the migration and invasion ability of 
endothelial cells
Angiogenesis plays an important role in tumor growth
and metastasis. Angiogenesis consists of multiple steps
including endothelial cell proliferation, migration, inva-
sion and tube formation. To test whether THL could
inhibit angiogenesis, we first tested the effect of THL on
endothelial cell migration by Boyden chamber transwell
assay. Endothelial cells (HMEC-1 or HUVEC) plated on
the upper chamber containing serum-free medium were
allowed to migrate to the lower chamber containingChia et al. BMC Cancer 2010, 10:175
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Figure 1 THL inhibits the migration and invasion of MDA-MB-231, H1299, PC-3, and CT-26 cancer cells. A) Images of wound healing assays (× 
100 magnification). B) Wound healing assays indicate that THL inhibited the migration of various cancer cells dose-dependently. Values represent 
means ± SD, n = 3. *P < 0.05; **P < 0.001 versus untreated control. C) Boyden chamber transwell assays indicate that THL dose-dependently inhibited 
the migration of various cancer cells. Upper panel, images of migrated MDA-MB-231 cancer cells (× 200 magnification). Lower panel, quantitation of 
migrated cancer cells. The migrated cells were counted in six randomly selected microscopic fields (× 200 magnification). The relative migrated cell 
number was obtained by comparing the migrated cell number in the presence of THL with that in the absence of THL. Values represent means ± SD, 
n = 3. *P < 0.05; **P < 0.001 versus untreated control. D) THL dose-dependently inhibited the invasion of various cancer cells. The cells invaded to the 
lower chamber were counted in six randomly selected microscopic fields (× 200 magnification). The relative invaded cell number was obtained by 
comparing the invaded cell number in the presence of THL with that in the absence of THL. Value represent means ± SD, n = 2. *P < 0.05 versus un-
treated control.Chia et al. BMC Cancer 2010, 10:175
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Figure 2 THL inhibits the secretion of MMP-2, MMP-9 and uPA and the activity of ERK1/2 in cancer cells. A) Gelatin zymogram of concentrated 
conditioned medium from MDA-MB-231, H1299, PC-3, or CT-26 cancer cells treated with various concentrations of THL during 24-h incubation period. 
B) Gelatin zymogram showing direct inhibitory effect of THL on MMP-2 activity. C) Casein zymogram of concentrated conditioned medium from MDA-
MB-231 or H1299 cancer cells treated with various concentrations of THL during 24-h incubation period. D) Western blot analysis shows that THL in-
hibits the phosphorylation of ERK1/2 but not that of AKT in CT-26 cancer cells. CT-26 cells were treated with various concentrations of THL in serum-
free medium for 24 h. Western blot analysis of cell lysates was performed as described previously [66]. The blot was first probed with antibodies against 
phospho-ERK1/2 (cell signaling, Danvers, MA) and phospho-AKT (cell signaling), and then reprobed with antibodies against ERK1, ERK2 (Santa cruz, 
Santa Cruz, CA) and AKT (cell signaling). Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) served as an internal control for amounts of protein 
loaded on the gel.Chia et al. BMC Cancer 2010, 10:175
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MDA-MB-231 breast cancer cell-derived conditioned
medium (231-CM, serves as a chemo-attractant) plus
various concentrations of THL. As shown in Fig 4A, the
migration of HMEC-1 and HUVEC toward 231-CM was
suppressed by THL in a dose-dependent manner. This
inhibition of migration is not due to the cytotoxic effect
of THL, because the viability of these cells was not
affected by THL in the concentration range tested (see
Additional file 3: Supplemental figure S3). Together, these
data suggest that THL can inhibit the migration of
endothelial cells to cancer cells. We also investigated the
effect of THL on HMEC-1 invasion by using 231-CM as
chemo-attractant in a Matrigel-coated Boyden chamber
assay. As shown in Fig 4B, the number of HMEC-1 cells
invaded through the Matrigel-coated filter was reduced
by THL dose-dependently, indicating that THL can
inhibit the invasion ability of endothelial cells.
MMP-2 and uPA are known to play important roles in
endothelial cell invasion. We thus tested whether THL
could inhibit the secretion of MMP-2 and uPA in
endothelial cells. Zymography assays indicated that THL
dose-dependently inhibited the secretion of MMP-2 (Fig
4C) and uPA (Fig 4D) in HMEC-1 cells. VEGF is known
t o be  a b le  t o  i nduc e  M MP -2 e x pr ess io n i n e ndo t he l ia l
cells [62]. We thus tested whether THL could inhibit
VEGF-induced MMP-2 expression in endothelial cells.
The data shown in Fig 4E indicate that this is indeed the
case.
THL inhibits tube formation by endothelial cells
In the latter stage of angiogenesis, endothelial cells will
self-assemble into tubes to form new blood vessels. To
investigate the effects of THL on neovascularization,
HMEC-1 or HUVEC cells were cultured on the Matrigel-
coated plates in the presence of the angiogenic stimulator
(10% FBS) and various concentrations of THL for 5 h. As
shown in Fig 5A upper panel, HMEC-1 cells formed the
complete network structures in the presence of 10% FBS,
indicating that FBS can induce tube formation of
endothelial cells. In the presence of 10% FBS plus THL,
tubular formation by HMEC-1 was significantly inhibited
(Fig 5A, upper panel). The inhibitory effect of THL on
tube formation induced by FBS was quantitated by count-
ing the number of tubes. As shown in Fig 5A lower panel,
the extent of tubular formation of HMEC-1 and HUVEC
was reduced by THL in a dose-dependent manner. We
also tested whether THL could inhibit 231-CM-induced
tube formation by HMEC-1. 231-CM indeed could stim-
ulate tube formation in HMEC-1 cells (Fig 5B). THL
reduced the extent of tubular formation of HMEC-1 to
levels even lower than that in the absence of 231-CM and
this inhibition on tube formation was dependent on THL
concentration (Fig 5B).
THL inhibits angiogenesis in the Matrigel plug model
In order to investigate whether THL suppressed vascular-
ization in vivo, the Matrigel plug assay was performed. In
contrast to plugs without 231-CM (serves as an angio-
genic stimulator), plugs loaded with 231-CM exhibited
bright red color indicating that 231-CM can induce new
blood vessel formation in Matrigel plugs (Fig 6). In the
presence of THL, plugs showed light yellowish color indi-
cating the absence of angiogenesis (Fig 6, upper panel).
The extent of angiogenesis was quantified by measuring
the hemoglobin content in the plugs. The amount of
hemoglobin in the Matrigel plugs loaded with 231-CM
plus THL was much lower than that in the plugs loaded
with 231-CM alone (Fig 6, lower panel), suggesting that
THL can inhibit neovascularization in vivo.
THL inhibits the expression of HIF-1α and VEGF-A in MDA-
MB-231 breast cancer cells
In rapidly growing tumors, local hypoxic conditions
induce the expression of transcription factor HIF-1α,
which in turn activates the expression of VEGF in tumor
cells. The VEGF secreted by tumor cells then binds to and
activates the receptor on the surface of endothelial cells,
leading to endothelial cell proliferation, migration, inva-
sion, and eventually capillary tube formation. To suppress
new blood vessel formation in tumors, it is important to
inhibit the expression of HIF-1α and VEGF in tumor
cells. As shown in Fig 7A, THL dose-dependently inhib-
ited the hypoxia-induced HIF-1α expression in MDA-
Figure 3 THL inhibits the pulmonary metastasis of mouse CT-26 
cancer cells in Balb/c mice. A) Images of metastatic lung nodules fol-
lowing water or THL treatment. B) Quantitation of metastatic lung nod-
ules. *P < 0.05 versus water-treated mice. C) Histological appearance of 
representative lungs from normal (not injected with tumor cells), wa-
ter-treated, and THL-treated mice.Chia et al. BMC Cancer 2010, 10:175
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Figure 4 THL inhibits the migration and invasion ability of endothelial cells and inhibits the secretion of MMP-2 and uPA in endothelial 
cells. A) The Boyden chamber transwell assay indicates that THL can dose-dependently inhibit the migration of HMEC-1 and HUVEC endothelial cells. 
Upper panel, images of migrated HMEC-1 endothelial cells in the presence of various concentrations of THL (× 200 magnification). Lower panel, quan-
titation of migrated HMEC-1 and HUVEC endothelial cells in the presence of various concentrations of THL at 6 h post-seeding. The migrated cells 
were counted in six randomly selected microscopic fields (× 200 magnification). The relative migrated cell number was obtained by comparing the 
migrated cell number in the presence of THL with that in the absence of THL. Values represent means ± SD, n = 2. *P < 0.05 versus untreated control. 
B) The Matrigel-coated Boyden chamber transwell assay indicates that THL can dose-dependently inhibit the invasion ability of HMEC-1 endothelial 
cells. The cells that invaded and migrated to the lower chamber were counted in six randomly selected microscopic fields (× 200 magnification). The 
relative invaded cell number was obtained by comparing the invaded cell number in the presence of THL with that in the absence of THL. Values 
represent means ± SD, n = 2. *P < 0.05; **P < 0.001 versus untreated control. C) Gelatin zymogram of concentrated conditioned medium from HMEC-
1 endothelial cells treated with various concentrations of THL during 6-h incubation period. D) Casein zymogram of concentrated conditioned medi-
um from HMEC-1 endothelial cells treated with various concentrations of THL during 6-h incubation period. E) Gelatin zymography indicates that THL 
can inhibit VEGF-induced MMP-2 expression in HMEC-1 endothelial cells. The cells were cultured in serum-free medium without or with VEGF (50 ng/
ml) plus various concentrations of THL for 6 h.Chia et al. BMC Cancer 2010, 10:175
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Figure 5 THL inhibits the tube-formation ability of endothelial cells. A) THL dose-dependently inhibits FBS-induced capillary-like tube formation 
by HMEC-1 and HUVEC cells. Upper panel, images of FBS-induced tube formation by HMEC-1 cells in the presence of various concentrations of THL. 
Lower panel, quantitation of FBS-induced tube formation by HMEC-1 and HUVEC cells in the presence of various concentrations of THL. The number 
of tubes was counted in six randomly selected microscopic fields (× 200 magnification). The relative tube number was obtained by comparing the 
number of tubes formed in the presence of THL with that formed in the absence of THL. Values represent means ± SD, n = 2. *P < 0.05 versus untreated 
control. B) THL dose-dependently inhibits 231-CM-induced capillary-like tube formation by HMEC-1 cells. Upper panel, images of tube formation by 
HMEC-1 cells in various conditions. Lower panel, quantitation of tube formation by HMEC-1 cells in various conditions. The number of tubes was count-
ed at 5 h post-seeding in six randomly selected microscopic fields (× 200 magnification). The relative tube number was obtained by comparing the 
number of tubes formed in different conditions with that formed in the presence of 231-CM without THL. Values represent means ± SD, n = 2. #P < 
0.05 versus unstimulated control (in the absence of 231-CM and THL); **P < 0.001 versus 231-CM control (in the presence of 231-CM only).Chia et al. BMC Cancer 2010, 10:175
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MB-231 cancer cells. As a result, the amount of VEGF-A
secreted into the medium by MDA-MB-231 cells was also
reduced by THL in a dose-dependent manner (Fig 7B).
This inhibition of HIF-1α and VEGF-A expression is not
due to cytotoxic effect of THL, because under similar
hypoxic condition, THL treatment did not affect the via-
bility of MDA-MB-231 cells (see Additional file 4: Sup-
plemental figure S4). The conditioned media from the
THL-treated and untreated MDA-MB-231 cells were
tested for their potency to induce HMEC-1 tube forma-
tion. As shown in Fig 7C, the conditioned medium from
THL-treated MDA-MB-231 cells had much lower
potency to induce HMEC-1 tube formation than the con-
trol conditioned medium.
THL inhibits the growth of human MDA-MB-231 breast 
cancer xenografts in SCID mice
The preceding data promoted us to assess the anti-tumor
activity of THL in vivo. Female NOD-SCID mice were
subcutaneously injected with 3 × 106  MDA-MB-231
breast cancer cells. One week later, mice were randomly
divided into two groups: one group was intraperitoneally
administered with THL and another group received PBS.
Three weeks after tumor cell implantation, while the
PBS-treated mice started to lose their body weight gradu-
ally, the THL-treated mice did not (Fig 8A). The PBS-
treated mice appeared sick with bristly hair, in sharp con-
trast to THL-treated mice which looked much healthier
with smooth and shiny hair. We also found that the
growth of the tumors was slower in THL-treated mice
than in PBS-treated mice (Fig 8B). The tumors were
removed, photographed, and weighed at Day 36 after
tumor cell implantation. As shown in Fig 8C and 8D, the
tumors from THL-treated mice had much smaller size
and weight than those from PBS-treated mice. The IHC
analysis on tumor sections showed that tumors from
THL-treated mice contained fewer CD31-positive
stained microvessels than those from PBS-treated mice,
consistent with the notion that THL can suppress tumor
angiogenesis (Fig 8E). The TUNEL assay on tumor sec-
tions revealed that tumors from THL-treated mice con-
tained much more apoptotic cells than those from PBS-
treated mice (Fig 8F). Together, these data indicate that
THL can induce tumor apoptosis and suppress tumor
angiogenesis and growth in SCID mice. Since SCID mice
are immunodeficient, the induction of apoptosis and sup-
pression of tumor growth by THL does not require host
immune function and most likely results from the anti-
angiogenic or direct killing effect of THL.
Discussion
Advanced cancer is a multifactorial disease that accumu-
lates many genetic and epigenetic alterations affecting
multiple distinct regulatory circuits within cells. To treat
advanced cancer, there is a growing belief that combina-
tion therapy using multiple drugs targeting various cellu-
lar pathways would yield better outcomes than
monotherapies. In this respect, herbal cocktail which
contains various phytochemicals targeting multiple dys-
regulated pathways in cancer cells may provide an alter-
native/complementary way to treat cancers. In this study,
we demonstrated that the Chinese herbal cocktail THL
not only could inhibit the in vitro migration and invasion
ability of various cancer cells but also could inhibit the
metastasis of colon cancer cells to lung in mice. Angio-
genesis plays a critical role in the growth and metastasis
of tumors. Our data indicate that THL not only could
inhibit the migration, invasion, and tube formation ability
of endothelial cells but also could inhibit cancer cells to
secrete the pro-angiogenic factor VEGF-A. The in vivo
anti-angiogenic activity of THL was also demonstrated in
the Matrigel plug model and tumor xenograft in NOD-
SCID mice. Together, these data indicate that THL is a
potential cancer therapeutic agent and merits further
Figure 6 Effect of THL on the 231-CM-induced angiogenesis in 
Matrigel plugs in NOD-SCID mice. Upper panel, Representative pic-
tures of control (without 231-CM), 231-CM-containing, 231-CM+THL-
containing Matrigel plugs at Day 14 after implantation into mice. Low-
er panel, quantitation of hemoglobin level in the plugs. Values repre-
sent means ± SD, n = 5-7. **P < 0.001 versus 231-CM-containing plugs.Chia et al. BMC Cancer 2010, 10:175
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Figure 7 THL inhibits hypoxia-induced HIF-1α and VEGF-A expression in MDA-MB-231 breast cancer cells. MDA-MB-231 cells were cultured 
under normoxia or hypoxia (with 200 μM CoCl2, a hypoxia-mimetic agent, in the medium) in serum-free medium containing various concentrations 
of THL for 24 h. Protein level of HIF-1α in cell lysates was analyzed by Western blot A), and VEGF-A secreted into the conditioned medium was analyzed 
by ELISA B). For the secreted VEGF-A, values represent means ± SD, n = 4. **P < 0.001 versus untreated cells under hypoxia. The conditioned media 
from untreated and THL-treated cells under hypoxia were tested for their effect on HMEC-1 tube formation C).Chia et al. BMC Cancer 2010, 10:175
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Figure 8 THL inhibits the growth of human MDA-MB-231 breast cancer xenografts in SCID mice. Effect of THL on the body weight A), tumor 
growth B), final tumor size C), and final tumor weight D) of NOD-SCID mice subcutaneously inoculated with human MDA-MB-231 breast cancer cells. 
For body weight, values represent means ± SD, n = 4 - 5 mice per group. For tumor volume data, values represent means ± SD, n = 8 - 10 tumors per 
group. For tumor weight data, values represent means ± SD, n = 6 tumors per group. **P < 0.001 versus PBS-treated mice. E) THL inhibits the angio-
genesis of MDA-MB-231 tumors grown in NOD-SCID mice. Upper panel, images of CD31-positive stained microvessels in tumor sections of PBS- and 
THL-treated mice. Lower panel, quantitation of microvessels in tumor sections of PBS- and THL-treated mice. For each section, 4-6 randomly chosen 
fields were counted. Values represent means ± SD, n = 6 tumors per group. **P < 0.001 versus PBS-treated mice. F) THL induces the apoptosis of MDA-
MB-231 tumors grown in NOD-SCID mice. Upper panel, images of TUNEL and Hoechst 33258 staining of tumor sections from PBS- and THL-treated 
mice. Lower panel, quantitation of TUNEL-positive cells in tumor sections of PBS- and THL-treated mice. For each section, 4-6 randomly chosen fields 
were counted. Values represent means ± SD, n = 6 tumors per group. *P < 0.05 versus PBS-treated mice.Chia et al. BMC Cancer 2010, 10:175
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evaluation for preventive and therapeutic application to
human cancers.
The formation of distant metastasis is the main cause of
morbidity and mortality in patients with cancer. In recent
years, much effort has been taken to develop drugs that
can inhibit metastasis. However, till now promising anti-
metastatic agents are still lacking [5]. In this study, we
demonstrated that THL could inhibit the in vitro migra-
tion and invasion ability of breast, lung, prostate, and
colon cancer cells (Fig 1) and suppress the pulmonary
metastasis of colon cancer cells in mice (Fig 3). Our data
indicate that several activities of THL may account for its
inhibitory effect on cancer metastasis. Firstly, THL could
inhibit, in cancer cells, the expression and secretion of
MMP-2, MMP-9, and uPA (Fig 2A, C), which involve in
degradation of extracellular matrix and play important
roles in cancer cell migration and invasion [5,6,63]. Sec-
ondly, THL could inhibit the activity of MMP-2 directly
(Fig 2B). Thirdly, THL could inhibit, in cancer cells, the
activity of ERK1/2, key molecules of the ERK signaling
pathway that has been shown to promote tumor invasion
and metastasis [61,64] (Fig 2D). Fourthly, THL could
inhibit, in cancer cells, the expression of HIF-1α (Fig 7A),
a transcription factor that promotes metastasis by regu-
lating the expression of metastasis-related genes [10].
Together, these data suggest that THL has multiple anti-
metastatic activities and has the potential to be developed
into an anti-metastatic agent. This argument is further
supported by the observation that THL could inhibit
angiogenesis, a critical process for cancer cells to spread
to other organs.
We demonstrated that THL could suppress tumor
angiogenesis in immunodeficient NOD-SCID mice (Fig
8E). We also demonstrated that THL could inhibit in vivo
neovascularization in Matrigel plugs loaded with cancer
cell-derived conditioned medium (231-CM) (Fig 6). At
least two activities of THL may contribute to its anti-
angiogenic effect in tumors. Firstly, THL could directly
inhibit the migration, invasion and tube formation of
endothelial cells (Fig 4 and 5). Secondly, THL could
inhibit the secretion of pro-angiogenic factor by cancer
cells (Fig 7). With regard to the direct inhibitory effect on
endothelial cells, we have found that THL could inhibit
the expression of MMP-2 (Fig 4C) and uPA (Fig 4D) in
endothelial cells. MMPs and uPA are known to play a
critical role in endothelial cell migration and invasion
[8,63]. The inhibition of MMPs and uPA expression in
endothelial cells can lead to suppression of endothelial
cell migration and invasion. With regard to the effect of
T H L  o n  c a n c e r  c e l l s ,  w e  h a v e  f o u n d  t h a t  T H L  c o u l d
inhibit the secretion of VEGF-A by cancer cells (Fig 7B).
At least two mechanisms may account for THL inhibition
of expression of VEGF-A in cancer cells. Firstly, we found
that THL could inhibit the hypoxia-induced expression of
HIF-1α which is a transcriptional activator of the vegf-A
gene [10], in cancer cells (Fig 7A). Secondly, we found
that THL could inhibit, in cancer cells, the activity of
ERK1/2 (Fig 2D), which phosphorylates the transcription
factor Sp1 and causes the recruitment of Sp1 to the vegf-
A promoter [65]. Our finding that THL can inhibit cancer
cells to express HIF-1α and to secrete VEGF-A is impor-
tant in terms of suppression of tumor angiogenesis. To
induce neovascularization in tumors, tumor cells must
secrete pro-angiogenic factors, such as VEGF-A, which
attracts and guides sprouting neovessels into oxygen-
depleted regions of the tumor mass. The blocking of HIF-
1α and VEGF-A expression in tumor cells can thus lead to
inhibition of neovessel formation in tumors.
This study has identified multiple biological pathways
as potential targets of the anti-tumor activities of the
THL formula. It will be of interest to identify the active
chemical compounds in the formula that target these
pathways. We have started to fractionate THL by ethyl
acetate partition and silica gel column chromatography.
Our preliminary results indicated that several fractions of
THL could inhibit the migration/invasion ability of
H1299 cancer cells. Among them, fraction 4 had the
strongest activity in inhibiting H1299 migration/invasion
ability (data not shown). Experiments using high-perfor-
mance liquid chromatography to isolate active compo-
nents of fraction 4 are in progress. Conceptually, it will be
interesting and important to determine whether the anti-
metastatic and anti-tumor activities of THL can be
reconstituted by a few active chemical compounds identi-
fied from THL.
Conclusions
Chinese herbal cocktails designed to maximize the syner-
gistic and minimize the antagonistic interactions among
various phytochemicals present in different herbs may
have therapeutic efficacy against multifactorial diseases
such as cancer . In this study, we demonstrated that the
Chinese herbal cocktail THL could inhibit cancer metas-
tasis and angiogenesis by targeting multiple biological
and pathological processes in cancer cells. We also dem-
onstrated that THL, which was delivered one week after
tumor implantation, could exert anti-tumor effects but
had no adverse effect on body weight in immuno-com-
promised mice, implicating that THL has potential to be
used as a therapeutic agent for established tumors. More-
over, our preliminary results also indicated that oral
delivery of THL could inhibit tumor growth and induce
anti-tumor immunity in immuno-competent mice (J-L
Du and W-B Wang, data not shown). Together these data
suggest that THL is a promising cancer therapeutic agent
and merits further investigation.Chia et al. BMC Cancer 2010, 10:175
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Additional file 1 Supplementary figure S1. Effect of THL on the viabil-
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Additional file 2 Supplementary figure S2. THL inhibits the transcrip-
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